

Building Effective Life Sciences Innovation Ecosystems

2024 Innovation Week, Cape Town, Wednesday October 23

Mattias Karlsson Dinnetz
Senior Program Officer, IP for Innovators Department, WIPO

WIPO Capacity Building Programme



Key actors

- **Research Institutions and Universities:** Conduct basic and applied research, often collaborating with industry to translate findings into products.
- **Biotechnology and Pharmaceutical Companies:** Develop, manufacture, and market new drugs and therapies; often engage in R&D partnerships with academic institutions.
- **Government and Regulatory Bodies:** Provide funding, create policies, and regulate the development and approval of new drugs and technologies.
- **Venture Capital and Investment Firms:** Provide funding to startups and early-stage companies in the life sciences sector, often focusing on high-potential innovations.
- **Healthcare Providers and Clinicians:** Implement new therapies and technologies in clinical settings, providing feedback for further innovation.

Key Actors II

- **Anji Miller, CLP RTTP, Senior Partner, LifeArc, UK**
- **Sarah Carroll, CEO MariHealth (Pty) Ltd**
- **Kirsten Miller-Duys, Hyrax Biosciences Ltd**
- **Ashley Uys, CEO, Medical Diagnostech (Pty) Ltd**
- **Eric van der Walt, CINO, Watchmaker Genomics (Pty) Ltd**
- **David Gulley RTTP, Executive Diretor, TTO, Puerto Rico Technology & Research Trust**

Questions

- *How can universities and research institutions enhance collaboration with biotech and pharma startups to accelerate the commercialization of innovations?*
- *How can pharmaceutical companies and large biotech firms engage with startups to promote innovation while mitigating potential risks in partnerships?*
- *What are the most effective support measures that governments and funding bodies can implement to foster biotech startup growth, especially in early-stage development?*
- *What role does intellectual property play in the success of biotech and pharmaceutical startups, and what are the key challenges startups face in protecting and leveraging their IP within the life sciences innovation ecosystem?*